Indianapolis-based Eli Lilly announced a new discount program for its insulin products in December. By participating in the program, Blink Health has offered discounts of up to 40 percent on Eli Lilly insulins, including Humalog, since January. Express Scripts helped Blink Health arrange the discount, according to the report.
“As we evaluated market dynamics, we determined that moving forward independently would best serve our patients and pharma partners. Express Scripts granted our request,” a Blink Health spokesperson said in a statement to Becker’s Hospital Review.
The spokesperson noted patients will still be able to access the 40 percent discount on Eli Lilly insulins through Blink Health.
Express Scripts said in an emailed statement Blink Health asked to terminate the agreement “after they failed to live up to the contractual agreements they had struck with us.”
The company added: “We agreed to allow the agreement to be terminated. As we understand it, the reason they terminated the agreement is because they determined they did not want an exclusive relationship with us. This violated the terms of the agreement they originally signed with us.”
Blink Health denied the allegations, saying it “fulfilled all of its contractual obligations under the agreement.”
Express Scripts said it ultimately agreed, with Eli Lilly’s cooperation, to continue to extend the discounts through Blink until the end of this year, unless Blink elects to terminate the discounts at an earlier time.
More articles on supply chain:
Medical Design Excellence Awards names top medical devices of 2017
More than 48k bottles of Bristol-Myers’ blood thinner recalled over dosing error
Takeda Pharma taps AI platform for drug development
